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Abstract
Background: Dendritic Cells (DC) are potent antigen presenting cells with the ability to prime naïve T cells and convert 
them to cytotoxic T-lymphocytes (CTL). We evaluated the capability of autologous DCs transfected with total tumor 
and normal RNA to induce cytotoxic CTL as the preliminary step to design a DC-based vaccine in the esophageal 
squamous cell carcinoma (ESCC).
Methods: Monocytes-derived DCs were electroporated with either total tumor RNA or normal RNA. T cells were then 
primed with tumor RNA transfected DCs and lytic effects of the generated CTL were measured with Cytotoxicity assay 
and IFN-γ Release Elispot assay.
Results: Cytotoxicity was induced against DCs loaded with tumoral RNA (%24.8 ± 5.2 SEM) while in normal RNA-
loaded DCs, it was minimal (%6.1 ± 2.4 SEM) and significantly lower (p < 0.05). INF-γ secretion was more than 2-folds 
higher in tumoral RNA-loaded DCs when compared with normal RNA-loaded DCs (p < 0.05).
Conclusion: Electroporating DCs with tumor RNA generated tumor antigen presenting cells which in turn enhanced 
cytotoxic effects of the T cells against ESCC. This may be a useful autologous ex vivo screening tool for confirming the 
lytic effects of primed T cells on tumors and evaluate probable further adverse effects on noncancerous tissues. These 
data provide crucial preliminary information to establish a total tumor RNA-pulsed DC vaccine therapy of ESCC.
Background
Gastrointestinal cancers are the most frequent cancer
malignancy in the Iranian population with substantial
numbers of the patients reported from northern and
northeastern Iran. Esophageal squamous cell carcinoma
(ESCC) is the fifth leading cause of cancer-related deaths
in Iran [1]. Most cases of ESCC in Iran as well as many
other countries are diagnosed in advanced stages [2]. Sur-
gical treatment and adjuvant therapeutic modalities such
as chemo- and radiotherapy have only a minimal effect
on patient outcome and the overall 5-years survival rate is
less than 25%.
Immune system plays an important role in counterbal-
ancing against the malignant transformation and escape
from immunologic surveillance and the subsequent
immune privilege of tumor may account for the develop-
ment of some cancers including ESCC [3]. On the other
hand, the suggested correlation between the infiltration
of T cells in the tumor environment and good prognosis
demonstrated in several tumors represents a naturally
occurring adaptive immunity in cancer patients [4].
Immunotherapeutic strategies are designed and opti-
mized based on a better understanding of different
escape mechanisms. Nonfunctional presentation of
tumoral antigen and further suppression of an effective
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immune response is one of the most important mecha-
nisms of immune evasion which has been targeted in
designing a number of immunotherapeutic modalities.
Dendritic cells (DC) are professional antigen capturing
cells which initiate primary and further secondary
immune responses in vivo. Their unique functions are
mediated by priming the naïve T cells and cross-present-
ing various antigens. Maturation is an important charac-
teristic of DCs during which immature DCs, as
phagocytic cells capture foreign antigens at the site of
injury and become mature cells along the process of pre-
senting the antigen peptides on MHC class I and II mole-
cules [5]. Mature DCs will then migrate to local lymph
nodes to present antigens to naïve T cells and convert
them into effector cells of the immune system against
non-self antigens [6]. Taking advantage of this in vivo
model, incubation of DCs with tumor specific molecules
such as proteins, peptides, or lysates, or transfecting
them with nucleic acids encoding tumor specific antigens
is the basic concept of designing DC-based cancer immu-
notherapy [7].
Electroporation is assumed as the most efficient
method for delivering the genetic materials into the cells
[8]. In this procedure, a mixture of cells and mRNA are
pulsed at a specific voltage for a short period of time.
Resulting is a small pore on the cell membrane which
makes it possible to pass mRNA into the cells [9]. Gilboa
et al pulsed DCs with tumor antigen-encoding mRNA
and reported an effective therapeutic tumor vaccination
when it was administered in a murine model for the first
time [10]. Although various studies have tried to find a
specific tumor marker for ESCC, an appropriate marker
has yet to be found for the purpose of immunotherapy.
Therefore, in this study we loaded DCs with total mRNA
to transfer the genetic material. T cell response was eval-
uated after priming with DCs transfected with tumoral
mRNA from ESCC patients as a preliminary step to
establish a DC vaccine for ESCC.
Methods
Sample collection and RNA isolation
Four histologically-approved ESCC patients were
included in the study prior to any therapeutic interven-
tions. After obtaining informed consents, approximately
50 ml of blood was collected in heparinized vials for
extraction of peripheral blood mononuclear cells
(PBMCs). Tumoral tissue was microdissected and stored
in RNAlater (Qiagen, Hilden, Germany) until RNA
extraction. Corresponding normal tissue from the
affected esophagus was obtained using the same protocol.
Total RNA was extracted by RNeasy kit (Qiagen, Hilden,
Germany). RNA integrity was confirmed by electropho-
resis on agarose gel and the concentration and purity was
checked by spectrophotometry at 260 nm and 280 nm.
The study was approved by the Research Ethics Commit-
tee of Mashhad University of Medical Sciences.
Generation of dendritic cells
Peripheral blood mononuclear cells were obtained from
50 ml of heparinized whole blood via Ficoll-Hypaque
(Biosera Inc., East Sussex, United Kingdom). The genera-
tion of DCs was performed on CD14+ cells isolated by the
EasySep®  Human Monocyte Enrichment Kit without
CD16 Depletion (Stemcell Technologies, Vancouver,
Canada). Cells were seeded for 5 days into six-well plates
in RPMI1640 supplemented by 10% heat-inactivated FBS,
penicillin (100 U/ml), streptomycin (100 mg/ml), L-glu-
tamine (2 mM), sodium pyruvate, 2ME (2-Mercaptoetha-
nol) (50 mM), human Granulocyte Monocyte-Colony
Stimulating Factor (GM-CSF) 800 IU (R&D System Inc.,
Minneapolis, MN, USA) and IL-4 500 IU (R&D, USA).
GM-CSF and IL-4 were again added on the third day. The
production of immature DCs was detected by specific CD
markers using BD FACSCalibur (BD Biosciences, CA,
USA). Cells were electroporated with tumor or normal
mRNA on the sixth day, followed by the maturation of the
cultured DCs with TNF-α (50 ng/ml) 4 hours after elec-
troporation. Electroporated mature cells were analyzed
for transfection using flow cytometry after 24-48 hours.
FACS (Fluorescence-Activated Cell Sorting) analysis of 
immature DC
Immunofluorescence staining of monocyte-derived DC
with differentiation and activation markers was per-
formed for the phenotypic analysis of DCs. Anti-HLA
DR, CD1a, CD80, CD86, CD83, FITC-conjugated (Fluo-
rescein Isothiocyanate), and CD14 PE-conjugated (Phy-
coerytherin) mouse monoclonal antibodies (IQ
Company, Netherlands) were used for the FACS analysis.
Appropriate mouse PE/FITC isotype was used as nega-
tive control.
RNA electroporation
Prior to electroporation on day 6, immature DCs were
washed twice with the Opti-MEM medium (GibcoBRL,
Eggenstein, Germany) and resuspended to a final concen-
tration of 10 × 106 cells/ml. Subsequently, 100 μl of the
cell suspension was initially mixed with 2.5 μg of
Enhanced Green Fluorescent Protein (EGFP) mRNA per
106 cells to confirm the transfection procedure. After
confirming the transfection procedure, DCs were trans-
fected with 1.5 μg of tumoral mRNA per 106 cells or 1.5
μg of corresponding normal mRNA per 106 cells. Trans-
fection was performed using a BTX ECM830 square-
wave electroporator with a single 500 V/300 μs pulse
(Genetronics, San Diego, CA, USA).Gholamin et al. BMC Cancer 2010, 10:261
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After pulsing, all the cells were gently and immediately
removed from the cuvette and poured into 6 well plates,
in which the containing media was pre-warmed at 37°C.
For negative control of electroporation reaction, mock
DCs were electroporated under the same conditions but
without the addition of mRNA.
Generation of in vitro-transcribed EGFP mRNA
In order to confirm the gene transfer efficiency by the
electroporation method, in vitro-transcribed (IVT) EGFP
mRNA was applied as a reporter gene. pGEM4Z/GFP/
A64 plasmid containing the poly(A) template (kindly pro-
vided by Dr. E. Gilboa, University of Miami, FA, USA)
was utilized for in vitro transcription of EGFP mRNA.
This plasmid was transformed into E. coli T op10F and
purified with a QIAprep Spin Miniprep Kit (Qiagen,
Hilden, Germany). Following vector linearization by the
restriction enzyme SpeI and purification, DNA template
was used for in vitro transcription under the control of a
T7 promoter with the T7 RNA polymerase. In vitro
capped RNA was synthesized by the Message MACHINE
kit (Ambion, Austin, TX, USA) according to the manu-
facturer's instructions. The concentration and purity of
amplified EGFP RNA was evaluated by spectrometric
analysis of absorbance at 260 (A260) and 280 nm (A280)
and by 2% agarose/EtBr gel electrophoresis. The DCs
electroporated with IVT EGFP mRNA were directly
checked by fluorescent microscope and underwent FACS
analysis to evaluate the efficiency of transfection which is
represented by the percentage of transfected cells in a live
population. The introduction efficacy is calculated by
multiplying the percentage of viable cells by the transfec-
tion efficiency[11].
Induction of tumor-specific CTL using DCs transfected with 
tumor RNA
For CTL generation, the T-cell-enriched non-adherent
fraction of PBMCs was obtained after the DC plastic
adherence step was performed. T-Cells were suspended
in RPMI1640 with 10% fetal calf serum, 25 mM Hepes, L-
glutamine, and antibiotics. Of the T-cell-enriched
PBMCs, 2 × 106 cells were combined with 2 × 105 trans-
fected matured DCs and 10 ng/ml IL-7 in a total volume
of 2 ml, in the wells of a 24-well tissue culture plate and
cultured at 37°C in 5% CO2 for 8 days. IL-2 was added to
the culture in the third day at a concentration of 20 IU/
ml. After 8 days, the effectors were harvested, washed,
counted, and re-stimulated with newly transfected DCs.
Adding IL-2 and IL-7 with the same concentrations to the
culture, the cells were incubated for another 8 days to
successfully induce tumor specific CTL.
Cytotoxicity test
To determine cytotoxicity, the calcein-AM cytotoxicity
assay was performed. Prior to the cytotoxicity assay, tar-
get cells were re-suspended in RPMI-1640 complete
medium at a final concentration of 106 cells/ml and incu-
bated with 10 μM calcein-AM (Invitrogen inc., Grand
Island, NY, USA) for 30 min at 37°C with occasional shak-
ing, treated with 50 μg/ml of mitomycin C for 30 min,
and washed three times with RPMI-1640 medium. Effec-
tors and calcein-labeled targets were co-cultured in U
bottom 96-well plates in triplicates for 4 h at 37°C in a
total volume of 200 μl with various effector:target (E:T)
ratios i.e. 1:1, 3:1 and 9:1. Supernatant samples were mea-
sured using a fluorescence spectrophotometer (FP-6200,
Jasco, Japan; exciting filter: 485 ± 9 nm; band-pass filter:
530 ± 9 nm). Data were expressed as arbitrary fluorescent
units (AFU). Percent cytotoxicity of the assay was calcu-
lated by the following formula: [(test release - spontane-
ous release)/(maximum release - spontaneous release)] ×
100. The maximum release and spontaneous release rep-
resent calcein release from the targets in the medium,
with and without 2% Triton X-100, respectively.
IFN-γ release Elispot assay
The IFN-γ release Elispot assay was performed by an
Elispot kit (U-CyTech biosciences, Utrecht, Netherlands)
according to the manufacturer's instructions. Briefly, 96-
well plates with transparent membranes were coated with
50 μL primary anti-IFN-γ antibodies and incubated at
4°C for at least 18 h. After washing the plates with the
washing buffer five times, individual wells were blocked
for nonspecific binding with 200 μL RPMI containing
10% FBS at 37°C for 1 h. After removal of the blocking
solution, 4 × 104 responder T cells and 2 × 103 mitomy-
cin-treated stimulator cells were added in a total volume
of 200 μL RPMI medium containing 10% FBS. Stimulator
cells included DCs transfected with tumoral or normal
mRNA and also mock DCs. Each experimental condition
was plated in triplicates and incubated at 37°C in 5% CO2
for 24 h. Cultures were removed and the plates were
washed ten times with the washing buffer. One hundred
microliters of properly diluted biotinylated detection
anti-IFN-γ antibody was added to each well and incu-
bated overnight at 4°C. The plates were washed with the
washing buffer five times and 50 μl of labeled anti-biotin
antibody was added to each well and incubated at 37°C in
the dark for 1 h. Washing was repeated five times and
activator solutions were added to detect the sites of
cytokine secretion by revealing the black spots. The
plates were developed in the dark for 30 min. The reac-
tions were stopped by rinsing with tap water and spots
were imaged and counted at the final step.Gholamin et al. BMC Cancer 2010, 10:261
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Statistical analysis
Results were expressed as the mean ± SD. Statistical anal-
ysis of cytotoxicity and Elispot tests were conducted by
unpaired Student's t-test and paired Student t-test using
SPSS software (version 16). A value of p < 0.05 was con-
sidered statistically significant.
Results
After preliminary optimization and confirming efficient
gene transfer in one patient, a total of 3 patients were
enrolled in the study. All the patients were histologically
diagnosed as esophageal squamous cell carcinoma. Clini-
copathological features of the patients are demonstrated
in Table 1.
FACS analysis of monocyte-derived DCs
Immuno-phenotyping of the DCs was analyzed five days
after monocytes were cultured and required cytokines
were added. Specific CD markers including CD1a, CD14,
CD80, CD86, CD83, and HLA-DR were detected to con-
firm the generation of immature DCs. CD14 was
decreased to less than 1% and CD1a was increased to the
average of approximately 95%, representing transforma-
tion of monocytes into DCs. After 2 days, FACS analysis
was performed to detect specific CD markers of matured
DCs. CD83 was increased to an average of 58.9% con-
firming the maturation process. Results of the FACS anal-
ysis are shown in Table 2.
Electroporation efficacy represented by GFP mRNA 
transfection into DC
In order to establish the optimized gene delivery into
monocyte-derived DCs, the transfection efficacy of in
vitro  transcribed GFP mRNA into DCs was first con-
firmed. Successful GFP expression, as a reporter gene,
was assessed by fluorescent microscopy and FACS analy-
ses. The average viability percentage of the transfected
cell population was 94.5% as compared to 97.9% in mock
cells and the average transfection efficiency was 87.8%.
The flow cytometry results of patient 1 are presented in
Figure 1. The kinetic of GFP expression was analyzed
afterwards and an approximately 30% expression was
detected 96 h after electroporation.
Cytotoxicity results
Cytotoxicity of primed lymphocytes with tumoral
mRNA-loaded DCs in ESCC patients were assessed by
measuring the cytotoxicity of CTLs against DC targets
loaded with tumoral RNA, or normal RNA, or mock DC
as negative control. Cytotoxicity percentage against DCs
loaded with tumoral RNA ranged from 17.5 to 35.0. In all
the patients, significant differences were observed
between cytotoxicity against DCs loaded with tumoral
RNA and mock DCs (p < 0.05). Cytotoxicity against DCs
loaded with tumoral RNA was significantly higher than
the corresponding value for DCs loaded with normal
RNA for each patient separately and when the average of
the two groups were compared with paired t-test (24.8 ±
5.2 SEM and 6.1 ± 2.4 SEM, p < 0.05). The Cytotoxicity
results of the ESCC patients are shown in Figure 2.
Elispot results
Elispot assay was performed to reconfirm the significant
differences between tumoral and normal mRNA-loaded
DCs observed in the results of cytotoxicity assay. Specific
T cell activation and INF-γ secretion was more than 2-
folds higher in tumoral RNA-loaded DCs when com-
pared to normal RNA-loaded DCs in patients 3 and 4 (p <
0.05). For patient 2, Elispot assay was not performed due
to insufficient amount of DCs (less blood was possible to
obtain from the patient) and only cytotoxicity test was
performed. The results of the assay are shown in Figure 3.
Discussion
Due to its asymptomatic nature, ESCC is often diagnosed
in its advanced stages where the common therapeutic
modalities are not very effective and the 5-year survival
rates do not exceed 25%. Therefore, approaches to novel
therapeutic modalities seem to be an essential step to
improve the survival rate of ESCC patients. We have pre-
viously shown that immune escape is a frequent event in
the Iranian ESCC patients. This suggests that immuno-
therapy can be a potentially effective tool to reverse
Table 1: Clinicopathological characteristics of patients.
Patient Age Sex Tumor Location Tumor Grade TNM Classification
Patient 1 65 Male Middle M.D. T3N0M0
Patient 2 51 Female Middle M.D. T3N0M0
Patient 3 79 Male Middle M.D. T3N0M0
Patient 1 98 Male Middle W.D. T2N1M0
"M.D." represents moderately differentiated and "W.D." represents well differentiatedGholamin et al. BMC Cancer 2010, 10:261
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malignant transformation of cells by enhancing immune
responses [12].
Dendritic cells have a unique capacity to capture, pro-
cess, and present antigens that establish primary and sec-
ondary immune responses [13-15]. Taking advantage of
their capabilities, DC transfection with nucleic acids
encoding tumor specific antigens leads to processing and
presenting the antigens and consequently, activating
tumor-specific CTLs [6]. Considering this fact, DCs are
proposed as an effective target for vaccinating cancer
patients against tumor antigens and promoting an
immune response against tumors [16,17]. It has been
shown that RNA transfection of DCs offers numerous
advantages over transferring other molecules [18,19].
mRNA delivery system is an efficient method compared
to the viral vectors as they do not pose the problems asso-
ciated with viral vectors [20]. DCs can be introduced by
total tumoral mRNA and the identification of tumor
associated antigens (TAAs) or HLA-typing is not obliga-
tory [21] especially in cancers such as ESCC in which
wide variety of genotypic and phenotypic features lead to
lack of specific tumor markers in different populations
[20]. Loading total tumoral mRNA decreases the proba-
bility of immune escape via polyclonal activation of T
cells against varied range of tumor-specific antigens and
minimizes the consequences of antigen loss in mutant
tumor cell clones. As RNA has a short half-life and lacks
the ability to integrate into genome, many problems with
viral vectors are not encountered [14]. With regards to
gene expression, mRNA transfection is more efficient
than DNA transfection as it bypasses the transcriptional
regulation processes and has easy access to the cytoplas-
mic translation machinery when transferred into the cells
[22]. Both CD4+ and CD8+ T lymphocytes will be acti-
vated by tumoral RNA transfer into DCs [23]. Electropo-
ration has proved to be a more efficient method of gene
transfer than many other techniques [22]. Thus, the elec-
troporation method was utilized in order to achieve effi-
cient total mRNA transfer into DCs as the preliminary
step of a DC vaccine design for ESCC. In the present
study, the results of mRNA transfer efficiency with elec-
Figure 1 mRNA transfection of DC. GFP mRNA delivery into DCs of patient 1 with electroporation (500 V, 300 μs). FACS analysis of transfected DC 
and Mock as a control is shown. Viability percentage was 85.7% in transfected cells as compared with 93.9% in control Mock. Transfection efficiency 
was 79.8%.
Table 2: Phenotypic characterization of immature and 
mature DCs by flow cytometry.
% Immature DC % Mature DC
CD14 0.9 4.7
CD1a 94.9 94.6
CD80 11.49 39.29
CD86 31.37 76.06
CD83 10.84 58.94Gholamin et al. BMC Cancer 2010, 10:261
http://www.biomedcentral.com/1471-2407/10/261
Page 6 of 9
troporation (approximately 80%) were comparable to the
previous reports of highly efficient transfer applying the
same method [5,24].
Clinical trials using antigen-loaded DCs have been pub-
lished in various types of cancer including myeloid leuke-
mia [25], medullary thyroid carcinoma [26], metastatic
melanoma [27], pancreas cancer [28], colorectal cancer
[29] and other malignancies. To our knowledge, only
Millano et al ha ve reported DC thera py on two ESCC
patients in addition to five esophageal adenocarcinomas
with some technical variations compared to our study
[30]. Our results show that primed T lymphocytes have
obtained the capability to lyse the tumor RNA-loaded
DCs. The percentage of lysis varies between 17.5 and 35
in the E:T ratio of 9. A serious limitation of this study was
restricted amount of DCs since we were not able to per-
form leukophoresis in our patients. Many studies have
performed the cytotoxicity assay in higher ratios [31,32].
However, due to our restrictions in the available amount
of DCs, we did not perform the assay in higher ratios and
probably in higher E:T ratios, greater percentage of cyto-
toxicity might have been observed. Cytotoxicity percent-
age in the mock DCs, as in controls, was negligible.
Transfecting DCs with total tumor RNA brings up a
major concern of a consequent adverse effect through
breaking tolerance towards self antigens and thus
destructing effects on normal tissues as well. In the pres-
ent study, cytotoxicity against normal RNA-loaded DCs
was minor while lytic activity of primed T cells induced
by DCs loaded with tumor RNA was significantly higher
than normal RNA-loaded DCs in each patient and when
comparing the average of both groups by paired t-test.
Millano et al have reported enhanced lytic response
against some of the studied normal tissues in esophageal
adenocarcinoma suggesting the possibility of adverse
effects against normal tissues in esophageal cancer [30].
Therefore, a preclinical ex vivo autologous assessment
may be a wise step to include the beneficiary cases and
predict the possibility of the adverse effects.
Conclusion
In summary, we demonstrated that electroporating DCs
with tumor mRNA will enhance the cytotoxic effects of T
cells against tumor in ESCC patients. Enhanced cytotox-
icity induced by tumor RNA-loaded DCs is introduced as
a useful autologous ex vivo screening tool for confirming
the lytic effects of primed T cells on tumor and evaluates
probable further adverse effects on noncancerous tissues.
Enhancing cytotoxicity against tumoral cells is a crucial
preliminary step to establish a total tumor RNA-pulsed
DC vaccine therapy of ESCC.
Figure 2 Cytotoxicity assay results representing cytotoxic activi-
ty of CTLs induced by DC/tumor-mRNA. Cytotoxicity assay was per-
formed against DC/Tumor mRNA, DC/Normal mRNA and DC/Mock as 
targets at various effector:target (E:T) ratios assessed by Calcein-AM re-
lease assay. Experiments were repeated three times, and representa-
tive data of similar results are shown. For example, in the patient 3 
cytotoxicity against DC/Tumor-mRNA, DC/Normal mRNA and DC/
Mock were 22%, 2% and -1% respectively. *p < 0.05 (Tumor vs. Normal); 
** p < 0.05 (Tumor vs. Mock).Gholamin et al. BMC Cancer 2010, 10:261
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Figure 3 INF-γ secretion Elispot assay results. INF-γ spots are counted per 105 T cells. Results are recorded as mean number of INF-γ spots with 95% 
confidence interval (CI) indicated on the bars. Specific T cell activation and INF-γ secretion was more than 2-folds higher in DC/Tumor-mRNA when 
compared to DC/Normal-mRNA in both patients (p < 0.05).Gholamin et al. BMC Cancer 2010, 10:261
http://www.biomedcentral.com/1471-2407/10/261
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